Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 51 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
68 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
FERMEDICS from Gent, company number BE0698608846, closed financial year 2025 with a result of € -60,586 after tax. For that financial year FERMEDICS recorded a gross margin of € 204,395 and equity of € 14,782. Compared with financial year 2024, the result moved from € -34,834 to € -60,586. The company made a loss. The buffer shrank hard: equity is 80 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ 14,782
▼ 80% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -60,586
▼ 74 % more loss than in 2024
Profit after tax over the fiscal year.
€ 109,975
▼ 27% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -303,788.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 150
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 651,788
▼ 4% vs 2024
€ 95,767 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 55,995
▲ 56% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -117,017 | € 12,756 | € 40,436 | € 204,395 | ▲ € 163,959 |
| Profit after taxes | € -124,984 | € 4,342 | € -34,834 | € -60,586 | ▼ € 25,752 |
| Equity | € 105,861 | € 110,202 | € 75,368 | € 14,782 | ▼ 80% |
| Total debts | € 211,184 | € 841,428 | € 908,416 | € 999,944 | ▲ 10% |
| Cash | € 190,381 | € 141,330 | € 151,430 | € 109,975 | ▼ 27% |
| Retained profit | € -212,709 | € -208,368 | € -243,202 | € -303,788 | ▼ € 60,586 |
| Bank debt | € 100,937 | € 205,951 | € 680,330 | € 651,788 | ▼ 4% |
| Balance sheet total | € 317,044 | € 951,630 | € 983,784 | € 1,014,726 | ▲ 3% |
Key figures of FERMEDICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FERMEDICS?
What happened at FERMEDICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 60,586. Source: NBB ↗
- Benoit Daems became a director. NBB
- Reinhard Verlinden became a director. NBB
- Lucas Decuypere became a director. NBB
- New establishment in Gent. KBO
- Jozef Verplaetse became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 124,984 loss in 2022 to € 60,586 loss in 2025.
Best year ever: 2023, with € 4,342 profit.
A new publication or filing at FERMEDICS? We notify you, reason included.
Follow FERMEDICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of DEBOFIN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
FERMEDICSBehind FERMEDICS are Jozef Verplaetse, Benoit Daems, Reinhard Verlinden and Lucas Decuypere. The shares are held by DEBOFIN (12.5%).
Directors
According to the 2025 annual accounts
Jozef Verplaetse
Director
since 2018
since 2021
Reinhard Verlinden
Director
since 2021
since 2021
Shareholders
12.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gaston Crommenlaan 8
9050 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 68 companies are registered at this address.
All companies at this address →ELDEMAR
€ 4.8 million gross margin · 2025
Petanque Mouscron
Iptor Belgium
€ 6.2 million revenue · 2025
1Enclose
€ 43,088 gross margin · 2025
FLUKE BELGIUM
€ 11.4 million revenue · 2025
+63 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
LEVEL27-AS * Please direct all complaints to [email protected] *, BE
Domain
Domain
fermedics.com
Registered
2018-03-16
Registrar
NameSilo, LLC
Expires
2027-03-16
Website info
Features
Security
Network
Details
- Company number
- 0698.608.846
- VAT number
- BE 0698.608.846
- Registered office
- Gaston Crommenlaan 8, 9050 Gent
- Names & denominations
- FERMEDICS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 June 2018
- Peppol
- Active · Active since 9 May 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van andere voedingsmiddelen, neg
Handelsbemiddeling in de groothandel in voedings- en genotmiddelen